Introduction -Abstract
Fiberoptic intubation with the awakened patient (Awake Fibreoptic Intubation [AFOI] ) is the gold standard technique for difficult airway management. The threshold for adopting AFOI depends, to some extent, on the competence of the person who will perform the intubation. The technique frequently requires sedation, anxiolysis and relief of discomfort without impairing ventilation and depressing cardiovascular function, a patent airway with blunting reflexes and spontaneous ventilation, especially when the airway is difficult. Many agents like fentanyl, midazolam, ketamine, propofol and remifentanil have been used to facilitate AFOI, but dexmedetomidine, α2 adrenoreceptor agonist with combined sedative, analgesic, anxiolytic and sympatholytic properties and without significantly depress effect over the ventilatory drive, has many properties to make it suitable for use during this technique.
The management of difficult airway is one of the most challenging tasks for the anesthesiologist. Awake Fibreoptic Intubation (AFOI) still is underutilized because some patients will reject AFOI and others, particularly children, may be unable to cooperate (1) . Moreover, fibreoptic intubation is a procedure which requires familiarity with the equipment and an understanding of airway endoscopic anatomy (2).
In patients with a possible or secure difficult airway, such as those presenting positive predictors, deformities or tumors in the airway, airway lesions, instability of the spinal cord, or antecedents of a previous difficult airway, AFOI is an effective and reliable technique to manage the difficult airway. In such situation, AFOI requires proficiency in providing efficient topical anesthesia and sedation techniques during the procedure in order to maintain the patient's airway cooperation and reduced anxiety, minimizing discomfort or serious adverse effects during the procedure (3). Dexmedetomidine was approved by the Food and Drug Administration at the end of 1999 for use in humans as a shortterm medication (<24 hours) for analgesia and sedation in the Intensive Care Unit (ICU), and in 2008 for sedation in nonintubated patients.
Its unique properties render it suitable for sedation and analgesia during the whole perioperative period. Its applications as a premedication, as an anesthetic adjunct for general and regional anesthesia, and as a postoperative sedative and analgesic are similar to those of the benzodiazepines, but a closer look reveals that the α2-adrenoceptor agonist has more beneficial side effects (12, 13) .
It is a highly selective, potent α2 adrenergic agonist. It has sedative, analgesic and anxiolytic properties, and reduced salivary secretion, with minimal respiratory depression. And has been used clinically for its sympatholytic, analgesic and sedative effects (14) (15) (16) (17) .
Dexmedetomidine does not cause clinically relevant respiratory depression and provide hemodynamic and sympathoadrenal stability by reducing the circulating catecholamines, attenuating the response to endotracheal intubation but without completely abolish the cardiovascular response (18, 19) . A sedation regimen using low dose dexmedetomidine combined with titrated doses of benzodiazepines and ultrashort acting narcotics with local airway anesthesia has been used for airway manipulation. A target controlled infusion can provide consistent pharmacodynamics effects with a safe and predictable sedation level (20) .
Dexmedetomidine has been used for intraoperative sedation during surgery under regional anesthesia, for sedation to mechanically ventilated patients in intensive care units, and for sedation during procedures, including AFOI (21-23). In two recent trials dexmedetomidine significantly reduced patient discomfort during AFOI with no significant differences in intubation time, airway obstruction, low oxygen levels or treatment-emergent cardiovascular adverse events (24) (25) (26) .
Dexmedetomidine could provide sedation and anxiolysis via receptors within the locus coeruleus, which is an important modulator of wakefulness (27) . The α2-adrenergic receptor mediates its effects by activating guanine-nucleotide regulatory binding proteins (G proteins). Activated G proteins modulate cellular activity by signaling a second messenger system or by modulating ion channel activity. The second messenger system, when activated, leads to the inhibition of adenylate cyclase, which, in turn, results in decreased formation of 3,5-cyclic Adenosine Monophosphate (cAMP). Specific cAMP-dependent kinases modify the activity of target proteins by controlling their phosphorylation status (28) . Modulation of ion channel activity leads to hyperpolarization of the cell membrane. Efflux of potassium through an activated channel hyperpolarizes the excitable membrane and provides an effective means of suppressing neuronal firing. Stimulation of the α2 adrenoceptor also suppresses calcium entry into the nerve terminal, which may be responsible for its inhibitory effect on secretion of neurotransmitters. From an anesthesiologic viewpoint, neuronal hyperpolarization is a key element in the mechanism of action of α2-adrenoceptor agonists (29) (Figure 2 ).
Findings lead to the conclusion that the major sedative and antinociceptive effects of dexmedetomidine are attributable to its stimulation of the α2 adrenoceptors in the locus coeruleus. The locus coeruleus is also the site of origin for the descending medullospinal noradrenergic pathway, known to be an important modulator of nociceptive neurotransmission. In this region of the brain, α2-adrenergic and opioidergic systems have common effector mechanisms, indicating that dexmedetomidine has a supraspinal site of action.
Dexmedetomidine, an imidazole compound, is the pharmacologically active dextroisomer of medetomidine that displays specific and selective α2-adrenoceptor agonism. Activation of the receptors in the brain and spinal cord inhibits neuronal firing, causing hypotension, bradycardia, sedation, and analgesia. The responses to activation of the receptors in other areas include decreased salivation, decreased secretion, and decreased bowel motility in the gastrointestinal tract; contraction of vascular and other smooth muscle; inhibition of renin release, increased glomerular filtration, and increased secretion of sodium and water in the kidney, decreased intraocular pressure, and decreased insulin release from the pancreas (30) .
Presynaptic activation of the α2adrenoceptor inhibits the release of norepinephrine, terminating the propagation of pain signals. Postsynaptic activation of α2 adrenoceptors in the Central Nervous System (CNS) inhibits sympathetic activity and thus can decrease blood pressure and heart rate. Combined, these effects can produce analgesia, sedation, and anxiolysis. Dexmedetomidine combines all these effects, thus avoiding some of the side effects of multiagent therapies.
The alpha-2/alpha-1-adrenoceptor selectivity ratio is eightfold greater than for clonidine, the classic alpha-2-adrenoceptor agonist (31) . Dexmedetomidine has a half-life (t1/2) of approximately two hours, a duration of action of approximately four hours and a side effect profile that is shorter in duration than that of clonidine (i.e. much shorter influence on normal physiology) (32, 33) .
Dexmedetomidine hydrochloride is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89.Have a rapid distribution phase, with a distribution half-life (t1/2) of approximately 6 minutes, and a terminal elimination half-life (t1/2) of approximately 2 hours. Peak plasma: 0.3-1.5 ng/mL. Protein bound: 94% Vd: 118 L Metabolism: Liver, including glucuronidation and CYP2A6 Metabolites: 3-hydroxy, 3-carboxy, 3-hydroxy N-methyl, 3-carboxy N-methyl, and N-methyl O-glucuronide dexmedetomidine. Total body clearance: 39 L/hr. The mean body weight associated with this clearance estimate was 72 kg. Dexmedetomidine undergoes almost complete biotransformation with very little unchanged dexmedetomidine excreted in urine and feces. Biotransformation involves both direct glucuronidation as well as cytochrome P450 mediated metabolism. Excretion: Urine (95%), feces (4%) (32, 33) .
When used at higher doses, dexmedetomidine exhibits minimal respiratory depression (34, 35) . Thus, dexmedetomidine has been proposed as a promising drug to use during AFOI for managing patients with a difficult or unstable airway (36) (37) (38) . Dexmedetomidine has been approved for use in intubated and mechanically ventilated patients in the intensive care unit (ICU), as well as in non-intubated patients undergoing surgical or other procedures (30) .
Although dexmedetomidine has beneficial attributes, increasing concentrations of dexmedetomidine in humans results in bradycardia and a biphasic (low, then high) dose-response relation for mean arterial pressure, especially in patients with intrinsic or drug induced bradycardia, hypovolaemia, advanced heart block or severe ventricular dysfunction (30) .
Alpha selectivity is observed in animals following slow intravenous infusion of low and medium doses (10-300 mcg/ kg). Both alpha and alpha activity is observed following slow intravenous infusion of high doses (≥1000 mcg/kg) or with rapid intravenous administration. It is recommended that dexmedetomidine be administered at a loading dose of 1 mcg/kg for at least 10 minutes, followed by a maintenance infusion of 0.2 to 0.5 mcg/kg/h. Dexmedetomidine exhibits linear kinetics in the dosage range of 0.2 to 0.7 mcg/kg/hr when administered by IV infusion for up to 24 hours. Table 1 shows the main pharmacokinetic parameters when Dexmedetomidine is infused (after appropriate loading doses) at maintenance infusion rates of 0.17 mcg/kg/hr (target concentration of 0.3 ng/mL) for 12 and 24 hours, 0.33 mcg/kg/hr (target concentration of 0.6 ng/mL) for 24 hours, and 0.70 mcg/ kg/hr (target concentration of 1.25 ng/mL) for 24 hours (32,33). 
1.
Dilution: 1 ampoule of 10 ml (1,000 mcg = 1 mg) in 40 ml of sodium chloride (50 mL total = 20 mcg/ml = 0.002 mg/ml).
2.
Adjust the dose to achieve a RSS 2 -3 (table3 and figure 3 ):
a.
Start the infusion at 1 mcg/kg/h (2-5 ml/hr) over 10 min (Loading Dose).
b. After 10 min, continue at 0.7 mcg/kg/hr (1.3 -3.5 ml/h) (Maintenance Infusion).
c.
After 5 min (15 min after initiating infusion) and every 3 min thereafterAssess Sedation Level. Target à RSS 2 -3:
i. Usual dose 0.5 mcg/kg/hr (1-2.6 ml/h).
ii. Usual dosage range: 0.4 -0.7 mcg/kg/hr (0.7 -3.5 ml/hr).
3.
Do not exceed the dose of 1.4 mcg/kg/hr (2.8 -7 ml/hr).
Habitual dosage (Table 2):
-Initial dose: 0.7 mcg/kg/hr.
-Dosage range: 0.2-1.4 mcg/kg/hr.
-Usual dose: 0.5 mcg/kg/hr.
-Drug presentations in our hospital are Ampoules of 2 with 100 mcg/ml (200 mcg per ampoule), or 10 ml ampoules with 100 mcg/ml (1000 mcg per ampoule = 1 mg).
-Cost in Spain: 4 ampoules of 10 ml have an approximate cost of 360 euros. But we must remember that it is not a harmless drug. Dexmedetomidine should be administered only by persons skilled in the management of patients in the intensive care or operating room setting. Due to the known pharmacological effects of Dexmedetomidine, patients should be continuously monitored while receiving Dexmedetomidine.
Caution should be exercised when administering Dexmedetomidine to patients with advanced heart block and/ or severe ventricular dysfunction. Because Dexmedetomidine decreases sympathetic nervous system activity, hypotension and/or bradycardia may be expected to be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension and in elderly patients (33).
Some patients receiving Dexmedetomidine have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms.
In terms of adverse reactions, rates observed in the clinical trials of a drug cannot be directly compared to rates in studies of another drug, and may not reflect the rates observed in practice. Use of Dexmedetomidine has been associated with the following serious adverse reactions:
I. Hypotension, bradycardia and sinus arrest. Clinically significant episodes of hypotension, bradycardia and sinus arrest have been reported with Dexmedetomidine administration in young, healthy adult volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration. If medical intervention is required, treatment may include decreasing or stopping the infusion of Dexmedetomidine, increasing the rate of intravenous fluid administration, elevation of the lower extremities, and use of pressor agents. Because Dexmedetomidine has the potential to augment bradycardia induced by vagal stimuli, clinicians should be prepared to intervene. The intravenous administration of anticholinergic agents (e.g., atropine) should be considered to modify vagal tone. In clinical trials, glycopyrrolate or atropine were effective in the treatment of most episodes of Dexmedetomidineinduced bradycardia. However, in some patients with significant cardiovascular dysfunction, more advanced resuscitative measures were required.
II. Transient hypertension has been observed primarily during the loading dose in association with the initial peripheral vasoconstrictive effects of Dexmedetomidine. Treatment of the transient hypertension has generally not been necessary, although reduction of the loading infusion rate may be desirable.
Most common treatment-emergent adverse reactions, occurring in greater than 2% of patients in both Intensive Care Unit and procedural sedation studies, include hypotension, bradycardia and dry mouth (13) .
Respect to the risk of over dosage, the tolerability of Dexmedetomidine has been established in a recommended dose of 0.2 to 0.7 mcg/kg/hr. in one study with healthy adult subjects. Doses above approximately 13 times the upper boundary of the therapeutic originate first degree atrioventricular block and second degree heart block. No hemodynamic compromise was noted with the atrioventricular block and the heart block resolved spontaneously within one minute (13, 15, 17, 26, 32, 33) .
Contraindications: Hypersensitivity to Dexmedetomidine.
-Second or third-degree AV block without pacemaker.
-Bradycardia <55 bpm.
-Fluid refractory hypotension and need for noradrenaline at doses> 0.5 mcg/kg/minute.
-Dysautonomy (e.g. spinal cord injury).
In conclusion, as all we know where FOI is considered the optimal method of securing the airway, an awake technique should be considered unless contraindicated. But AFOI can fail due to a number of factors including poor co-operation, inappropriate sedation, bleeding and inability to identify anatomy and airway obstruction. Fibreoptic intubation is most effective in co-operative patients. Airway patency and co-operation may be lost by over-sedation. Where complex sedation techniques are to be used, strong consideration should be given to delegating the provision of sedation to an anaesthetist not performing the tracheal intubation.
Dexmedetomidine is a highly selective, potent α2 adrenergic agonist, with sedative, analgesic and anxiolytic properties that reduced salivary secretion with minimal respiratory depression. So that it seems to be a good option… and only time will tell us if it displaces the other techniques.
